{"id":"62f6c0959b12","type":"article","url":"https://hartvaat.nl/2026/03/03/kdigo-versnelt-richtlijnontwikkeling-voor-nierziekten/","title":"KDIGO versnelt richtlijnontwikkeling voor nierziekten","title_en":"","category":"chronische nierziekte","category_label":"Nierziekte","professions":["cardioloog","internist"],"tags":["cardiorenal-behandelstrategie","diabetes-en-hart","farmaco-economie","fidelio-dkd","richtlijnen-esc"],"journal":"Kidney International","doi":"https://www.kidney-international.org/article/S0085-2538(26)00012-8/fulltext","source_url":"https://doi.org/https://www.kidney-international.org/article/S0085-2538(26)00012-8/fulltext","authors":["Morgan E. Grams","Michel Jadoul"],"significance":6,"published":"2026-03-27","source_date":"2026-03-03","image":"","kennis":["https://hartvaat.nl/kennis/nierziekte/kdigo-richtlijn-ckd-2024/","https://hartvaat.nl/kennis/cardiometabool/esc-richtlijn-diabetes-cvd-cardiometabool/"],"congress":"","summary_en":"KDIGO has published 17 kidney disease guidelines, but traditional full-revision cycles take years and lag behind rapidly evolving therapies such as SGLT2 inhibitors and finerenone. This article describes KDIGO's transition to modular, faster guideline updates to accelerate evidence translation into cardiometabolic clinical practice.","created":"2026-07-03T10:32:39Z","updated":"2026-07-03T13:31:35Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies.","body_markdown":"KDIGO heeft 17 richtlijnen voor nierziekten gepubliceerd, maar het traditionele proces van volledige herziening duurt jaren. Gezien de versnelde ontwikkeling van nieuwe therapieën (SGLT2-remmers, finerenon) stapt KDIGO over op modulaire, snellere updates. Dit artikel beschrijft de strategie om evidencetranslatie naar de kliniek te versnellen, wat direct relevant is voor de cardiometabole praktijk.","abstract_original":"Kidney Disease: Improving Global Outcomes (KDIGO) develops evidence-based clinical practice guidelines to improve care for people with kidney disease worldwide. KDIGO has produced 17 guidelines across kidney care, and 7 of these have been updated comprehensively at least once. Historically, guidelines were revised in their entirety when novel therapies or treatment paradigms emerged—a process requiring years to complete. To respond more dynamically to accelerated clinical trial results and drug approvals, KDIGO recently adopted a modular update approach for some guidelines."}